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ABSTRACT
Aims To evaluate the cost-effectiveness of a specialist smoking cessation package for people with severe mental illness
Design Incremental cost-effectiveness analysis was undertaken from the UK National Health Service and Personal So-
cial Services perspective over a 12-month time horizon. Total costs, including smoking cessation, health-care and social
services costs and quality-adjusted life years (QALYs), derived from the five-level EuroQol 5-dimension (EQ-5D-5 L), col-
lected from a randomized controlled trial, were used as outcome measures. The bootstrap technique was employed to as-
sess the uncertainty. Setting Sixteen primary care and 21 secondary care mental health sites in England.
Participants Adult smokers with bipolar affective disorder, schizoaffective disorder or schizophrenia and related illnesses
(n = 526). Intervention and comparator A bespoke smoking cessation (BSC) package for people with severe mental ill-
ness offered up to 12 individual sessionswith amental health smoking cessation practitioner versus usual care (UC). Of the
participants who were randomized, 261 were in UC group and 265 were in BSC group.Measurements BSC interven-
tion cost was estimated from the treatment log. Costs of UC, health-care and social services and EQ-5D-5 L were collected
at baseline, 6- and 12-month follow-ups. Incremental costs and incremental QLAYs were estimated using regression
adjusting for respective baseline values and other baseline covariates. Findings The mean total cost in the BSC group
was £270 [95% confidence interval (CI) = –£1690 to £1424] lower than in the UC group, while the mean QALYs were
0.013 (95% CI = –0.008 to 0.045) higher, leading to BSC dominating UC (76% probability of cost-effective at
£20000/QALY). Conclusions A bespoke smoking cessation package for people with severe mental illness is likely to
be cost-effective over 12 months compared with usual care provided by the UK’s National Health Service and personal so-
cial services.
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INTRODUCTION
In 2018/19, Public Health England reported adult
smoking prevalence in the general population as 14.5%,
while in adults with long-term mental health conditions
it was 26.8% [1]. The most recent estimate for smoking
prevalence in adults with severe mental illness (SMI) was
40.5% in 2014/15 [1]. While the likelihood and intensity
of smoking are higher in this population [2], smokers with
SMI are less likely to receive help in quitting [3]. As
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smoking is the most important modifiable risk factor in
health, this contributes to the widening health inequality
suffered by people with SMI [4].
Facing this challenge, the importance of smoking cessa-
tion in people with SMI has been stressed and relevant
goals have been set out, but little guidance is provided on
how to tailor smoking cessation services in the United
Kingdom (UK) to cater for the needs of this population
[5,6]. Trial-based evidence suggests that behavioural sup-
port and pharmacotherapies can be as effective in helping
people with SMI to quit as the general population [7].
We conducted a 12-month pragmatic two-arm parallel
group individually randomized controlled trial (RCT) to
compare a bespoke smoking cessation (BSC) intervention
(n = 265) with usual care (UC) (n = 261) (SCIMITAR+
trial). The report of the project has been published in full
in health technology assessment [8]. The protocol has been
published previously [9]. The carbon monoxide (CO)-veri-
fied quit rate at 6 month was 11% in the BSC group and
5% in the UC group, and at 12 months was 13% in the
BSC group and 8% in the UC group [10]. The unadjusted
odds ratio at 6 months was 2.4 [95% confidence interval
(CI) = 1.3–4.7] and at 12 months was 1.6 (95%
CI = 0.9–2.8). This article reports the analyses to (1) eval-
uate cost-effectiveness of BSC from a UK National Health
Service (NHS) and Personal Social Services (PSS) perspec-
tive; and (2) observe if the costs of antipsychotic prescrip-
tion change with smoking status.
METHODS
Study design
An incremental cost-effectiveness analysis was under-
taken alongside the RCT to assess the cost-effectiveness
of BSC in comparison with UC. The costs included
smoking cessation treatment costs (BSC/UC) and
health-care and social services costs. The effectiveness
was measured in terms of quality-adjusted life years
(QALYs). Ethical approval for the trial was granted by
NRES Committee Yorkshire and The Humber–Leeds East
REC (15/YH/0051) on 19 March 2015.
Intervention and comparator
The BSC intervention was a specialist smoking cessation
package delivered by trained mental health smoking cessa-
tion practitioners (MH-SCPs), who were experienced men-
tal health clinicians. The intervention was in line with the
National Institute for Health and Care Excellence (NICE)
guidelines [11] at the time of the trial and was delivered ac-
cording to the Manual of Smoking Cessation developed by
the National Centre for Smoking Cessation Training
(NCSCT) [12] in the UK, with adaptations to cater for
people with SMI [13]. It was developed and tested in the
context of a feasibility RCT [14].
All participants remained under the care of their pri-
mary care physician and continued to receive routine care
from mental health team. Participants allocated to the
BSC group were offered up to 12 individual face-to-face
support sessions with a MH-SCP (approximately 30 mi-
nutes each) in their home or NHS premises. MH-SCPs ad-
vised participants on available pharmacological smoking
cessation aids and liaised with the participants’ primary
care physicians who would make decisions on prescribing
pharmacotherapies chosen by participants. Participants
allocated to the UC group were advised to seek help from
their primary care physician and local Stop Smoking Ser-
vice (SSS). No additional treatment was offered in the con-
text of the SCIMITAR+ trial.
All participants had access to the full range of
smoking cessation treatments offered by local authorities
(LA) and the NHS. However, participants in the BSC
group were asked not to take other treatments before
the intervention ended.
Participants
Participants were recruited from 21 mental health trusts
and 16 primary care sites in England, UK. Eligible partici-
pants were: people aged 18 years and above, with SMI,
who smoked five or more cigarettes per day and expressed
an interest in cutting down or quitting smoking. The
adopted definition of SMI was a pragmatic one used in UK
primary care, i.e. schizophrenia or delusional/psychotic ill-
ness (ICD-10: F20 X and F22 X) or bipolar disorder (ICD-
10: F31 X) diagnosed by specialist mental health services
and documented in either primarycare records or psychiat-
ric notes before recruitment. People who were pregnant or
breastfeeding, had significant comorbid drug or alcohol
problems (as ascertained by primarycare physician ormen-
tal health worker), lacked capacity or were non-English
speakers were excluded. Written consent was signed and
dated by both participant and researcher at baseline.
Between October 2015 and December 2016, 265 par-
ticipants were randomized to the BSC group and 261 to
the UC group. The median age was 47.6 years [interquar-
tile range (IQR) = 35.5, 55.3] in the BSC group and
46.6 years (IQR = 36.5, 53.8) in the UC group. Male par-
ticipants consisted of 60% (159 of 265) of the BSC group
and 58% (150 of 261) of the UC group. Five participants
died before 6-month follow-up (three in BSC and two in
UC) and two in the UC group died after 6-month follow-up.
Masking
Due to the nature of the intervention, it was not possible to
blind participants, professionals involved in their care or re-
searchers to treatment allocation.
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Data collection
Costs
All costs are presented in 2016/17 pounds sterling (£).
Smoking cessation treatment cost. Costs of smoking cessa-
tion treatment consisted of cost of BSC intervention and
cost of usual care for the BSC group, while only cost of
usual care for the UC group. Cost of BSC intervention in-
cluded cost of BSC training and supervision and cost of
BSC delivery.
Four research staff took a 2-day training from the
NCSCTand then delivered a 2-day training session in pairs,
in line with the NCSCT to all MH-SCPs. The NCSCT train-
ing cost was estimated using the invoice. The time spent
by research staff on the NCSCT training and on training
MH-SCPs were costed at NHS band 6 to reflect the costs
in practice (£43/hour) [15]. The time spent by the
MH-SCPs was costed at NHS band 4 (£28/hour) [15].
These costs included salary on-costs, overheads and capi-
tal. A full working day was considered to be 7.5 hours.
Each MH-SCP was given a 43-page manual and a
51-page NCSCT standard treatment programme. These
were printed in-house at £0.02 per page. All MH-SCPs
had regular supervision from those who delivered the
training. Supervision timewas recorded by the supervisors.
Each MH-SCP was equipped with a £120 CO-monitor with
a 5-year life-time. The depreciation value of CO-monitors in
the first year was calculated using double-declining bal-
ance to estimate the cost of CO-monitors during the trial
period. The total BSC training, supervision and materials
costs were allocated to each participant in the BSC group.
The BSC delivery cost was estimated based on partici-
pants’ sessions with MH-SCPs. The treatment costs in the
BSC group further included contacts with usual care ser-
vices for smoking cessation after BSC ended. In the UC
group, the treatment costs were costs of contacts with
usual care services for smoking cessation only.
The length and location of BSC sessions were recorded
on treatment logs by MH-SCPs. An estimated 40 minutes
was added to the sessions where theMH-SCPs had to travel
to the appointment. An estimated 10 minutes was added
to each attended session to account for administrative
time. The costs of BSC delivery were calculated bymultiply-
ing the total hours spent by MH-SCPs by their hourly cost.
The costs of usual care services for smoking cessation
included participants’ contacts with primary care physi-
cians, pharmacists, SSS, SSS helpline and prescriptions of
pharmacotherapies for smoking cessation. The number
of contacts with these services were collected using
self-reported questionnaires at baseline, 6- and
12-month follow-up. It was then multiplied by a set of na-
tional average unit costs (Supporting information, Table
S1) [15–17]. The data on prescribed pharmacotherapies
during the trial period were extracted from participants’
medical records and matched to the Prescription Cost
Analysis England [18] by their generic name, dosage
and form to gain a weighted average net ingredient cost
(NIC) per unit, which was multiplied by prescribed quan-
tities. If dosage or form was missing, a weighted average
NIC matching available information was used instead.
Medications that had been extracted by number of pre-
scriptions were estimated based on weighted average
NIC per prescription item.
Health-care and social services costs. Participants’ use of
health-care and social services was collected by an adapted
Health Economic/Service Utilization questionnaire at base-
line, 6- and 12-month follow-up, which covered service
use for a 6-month period before each follow-up [19]. The
services included primary care, secondary care and
community-based services. The costs were estimated by
multiplying the quantities by their national average unit
costs extracted from secondary sources (Supporting infor-
mation, Table S1) [15,20,21]. Participants’ prescription
of antipsychotics during the trial period was extracted,
the costs of whichwere estimated using the same approach
as with prescribed pharmacotherapies.
Quality-adjusted life years (QALYs)
The five-level EuroQol 5-dimension (EQ-5D-5 L) instru-
ment was administered to all participants at baseline, 6-
and 12-month follow-up, as recommended by NICE guid-
ance [22]. It is a population preference-based measure of
health-related quality of life, developed by the EuroQol
Group [23], consisting of a descriptive system and a visual
analogue scale (VAS). The descriptive system comprises five
dimensions (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression), each with five levels
(no problems, slight problems, moderate problems, severe
problems and extreme problems). The complete set of five
digits (one for each dimension) was converted to a utility
score (0.594 to 1) using the crosswalk mapping function
based on the UKvalue set in line with the position of NICE
at the time of analysis [24,25]. QALYs were then derived
from utility scores at the three time-points by calculating
the area under the curve [26]. The VAS has a range of 0
to 100, measuring the self-perceived health on the day.
Missing data
Any missing values in the baseline variables were imputed
by the mean of the variable in the whole sample, as the
amount of missingness was expected to be very low and
to be independent of treatment allocation [27]. The miss-
ing values in the follow-up variables were handled by mul-
tiple imputation by chained equation (MICE) performed by
allocation, assuming missing at random (MAR) [28]. Pre-
dictivemeanmatchingwas used as the imputationmethod
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for continuous variables, using 10 nearest neighbours to
the prediction as a pool from which to draw. Binary vari-
ables were imputed using the logit method. The imputation
model included age, gender, study centre, existence of
pre-existing medical condition, duration since first diagno-
sis of SMI, duration since start of smoking, cost of BSC
training and supervision, cost of BSC delivery, cost of usual
care services for smoking cessation, cost of pharmacother-
apy prescriptions, cost of emergency and hospital services,
cost of primary and community services, cost of antipsy-
chotics prescription, cigarettes smoked per day, Fagerström
Test for Nicotine Dependence (FTND), EQ-5D utility, EQ-5D
VAS, travel expense, purchase of e-cigarettes and pur-
chase of nicotine replacement therapy (NRT) products.
As a rule of thumb, the number of imputations was
set to the highest percentage of all missing values [28].
For those who died during the trial period, the costs, ex-
penses, utility and EQ-5D VAS after the time of death
were replaced with zero, while the missing values before
the time of death were handled using the same imputa-
tion methods described above. The imputed data set was
analysed following Rubin’s rule [29].
Primary analysis
The primary analysis was conducted on an intention-to-
treat basis from an NHS and PSS perspective, as per NICE
guidance [22]. Neither costs nor QALYs were discounted,
as the evaluation period was 12 months.
The total costs included smoking cessation treatment
costs and health-care and social services costs over
12months. The difference inmean total costs (incremental
costs) and mean QALYs (incremental QALYs) between
groups was estimated by a mixed-effect generalized linear
model, using treatment group, age, gender, pre-existing
medical condition, duration since first diagnosis of SMI as
fixed effects and study centre as a random effect. For mean
total costs, smoking cessation and health-care and social
services costs in the 6 months before baseline were added
as an additional covariate, and for mean QALYs utility
value at baseline was added as an additional covariate
[30]. Incremental costs and incremental QALYs were then
assessed in combination. An incremental cost-effectiveness
ratio (ICER) was calculated by dividing incremental costs
by incremental QALYs where applicable. It was then com-
pared with the maximum acceptable ICERs of £20000–
30000, recommended by NICE [22].
The uncertainty surrounding incremental costs and
QALYs was assessed using a non-parametric bootstrap
technique, whereby 5000 replicate samples were gener-
ated by resampling [31]. Bootstrap was performed on the
imputed data set for the primary analysis, using the
methods described by Faria et al. [27]. Bootstrapped 95%
CIs were estimated for incremental costs and incremental
QALYs, respectively, while the combination of the two
was plotted on a cost-effectiveness plane (CEP) to illustrate
the uncertainty. Cost-effectiveness acceptability curves
(CEACs) were constructed from the bootstrapped replicates
by converting ICERs to net monetary benefit [32].
Sensitivity analyses
A complete case analysis (CCA) was undertaken to assess
the impact of missing values and the uncertainty was
assessed following the same approach used on the imputed
data set. MAR assumption was assessed using the pattern
mixture modelling approach [27] by assuming missing
not at random (MNAR) mechanism, i.e. those who did
not complete the service uses section of the questionnaire,
had higher costs and worse health condition. This was ex-
amined after multiple imputation by varying imputed
values, assuming: (1) imputed costs were increased by
10, 20 and 30% for those who did not complete services
use section; (2) imputed QALYs were reduced by 10, 20
and 30% for those who did not complete EQ-5D-5 L.
Secondary analysis
There was evidence suggesting that smokers with SMI
could reduce their intake of antipsychotics to achieve
the same effect after they stop smoking [2]. To verify this,
we conducted a before-and-after comparison of the costs
of antipsychotics. Limited by the data availability, we used
6-month follow-up as the point of change. The costs of
antipsychotics over 6 months before and after this point
could then be compared by smoking status. The smoking
status was classified to four categories: those quit at 6-
and 12-month follow-ups, those quit at 6-month but
not quit at 12-month follow-up, those not quit at
6-month but quit at 12-month follow-up and those quit
at neither follow-up. Only those who provided valid
smoking status information and whose cost of antipsy-
chotics were available were included. The comparison
was performed using Wilcoxon signed-rank test due to
the non-normal distribution of the costs.
All analyses were performed using Stata version
15.0 SE.
RESULTS
Smoking cessation treatment costs
Fifty-six mental health clinicians attended the 2-day BSC
training in eight groups. Supervision time was estimated
at 30 minutes per participant. The mean BSC training, su-
pervision and materials cost was £190 per participant in
the BSC group (Table 1).
Two participants had records missing values on BSC
sessions. Among the rest, the mean BSC delivery time
was 492 minutes [standard deviation (SD) = 339,
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range = 0–1425], including 27 participants who attended
no sessions. The mean cost of BSC delivery was £229
(SD = £158) per participant in the 263 participants in
the BSC group, with two participants missing.
The mean usage of usual care services for smoking ces-
sation was less than once per responding participant
within a 6-month period in both groups, and had a wide
variance at individual level (Supporting information,
Table S2). The mean cost of usual care services was £37
(SD = £60) among the 212 responding participants in
months 1–6 and £26 (SD = £59) among the 213
responding participants in months 7–12 in the UC group.
In the BSC group, it was £28 (SD = £62) among the 217
responding participants in months 1–6 and £23
(SD = £56) among the 212 responding participants in
months 7–12.
The prescription information on pharmacotherapies for
smoking cessation was returned for 160 of 261 (61%) par-
ticipants in the UC group and 156 of 265 (59%) partici-
pants in the BSC group. The information was insufficient
to extract NIC for four participants in the UC group and
17 participants in the BSC group, and their cost of pharma-
cotherapy prescription was considered missing. The
mean cost of pharmacotherapy prescription was £26
(SD = £73) among the 156 participants in the UC group
and £92 (SD = £198) among the 139 participants in the
BSC group, including those for whom none were pre-
scribed (115 of 156 in the UC group, 56 of 139 in the
BSC group).
Missing data
At 6-month follow-up, 207 of 261 (79%) in the UC group
and 208 of 265 (78%) in the BSC group completed the ser-
vices use section of questionnaire (Pearson’s χ2 test,
P = 0.818). At 12-month follow-up, 202 of 261 (77%) in
the UC group and 203 of 265 (77%) in the BSC group
did so (Pearson’s χ2 test, P = 0.829). The mean number
of use of health-care services was generally low with a
large standard deviation, except for primary care practice
visits (more than two over 6 months), community psychi-
atric nurse (more than five over 6 months), Community
Mental Health Team (more than four over 6 months) and
day care service (more than three over 6 months)
(Supporting information, Table S3). There were few miss-
ing data for baseline variables (≤ 2%). The highest percent-
age of missing values was 44% of the estimated costs of
pharmacotherapy prescription due to the lack of or
Table 1 Breakdown of intervention training and supervision cost in the BSC group.
Item Description Cost (2016/17) Sources
Training
Staff time
NCSCT training – £5325 in total Invoice by
NCSCT
Attending NCSCT training 7.5 hours/day × 2 days, 4 trainers (NHS band 6) £43/hour per trainer [13]
Training for MH-SCPs 7.5 hours/day × 2 days, 2 trainers (NHS band 6),
8 trainings held
£43/hour per trainer [13]
Trainees (NHS band 4) 56 trainees attending 2 days training
(7.5 hours/day)
£28/hour per person [13]
Costs of staff time £41745 in total
Printing
Manual 43 pages/trainee £0.02/page Team records
Treatment programme 51 pages/trainee £0.02/page Team records
Cost of printing £105 in total
Costs of training £158/participant
Equipment
CO monitor 56 × £120/device £6720 in total Team records
First year depreciation Function life 5 years £2688 in total
Cost of CO monitor £10/participant
Supervision
Supervisor (NHS band 6) 0.5 hours/participant £43/hour [13] Study
estimates
Cost of supervision £22/participant
Total training, supervision and material costs £190/participant
randomized
BSC = bespoke smoking cessation; NCSCT = National Centre for Smoking Cessation Training; MH-SCPs = mental health smoking cessation practitioners;
NHS = National Health Service; CO = carbon monoxide.
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insufficient data extraction from participants’ medical re-
cords. The number of imputations was set to 45.
Primary analysis
The mean cost of smoking cessation treatment per partic-
ipant, including BSC, usual care and pharmacotherapy
prescriptions, was £93 [standard error (SE) = £9) in the
UC group and £561 (SE = £19) in the BSC group. The
mean total costs over 12 months were £8489
(SE = £775) in the UC group and £8447 (SE = £596)
in the BSC group. The adjusted incremental costs were –
£270 (95% CI = –£1690 to £1424). The mean QALYs
over 12 months were 0.647 (SE = 0.017) in the UC group
and 0.664 (SE = 0.015) in the BSC group. The adjusted
incremental QALYs were 0.013 (95% CI = –0.008 to
0.045). This led to BSC dominating UC (less costly, more
effective) (Table 2, left).
The upper part of Fig. 1 presents the CEP (left) and
CEAC (right) constructed from 5000 bootstrapped repli-
cates for the primary analysis. The CEP shows that the
majority (4583 of 5000, 92%) of the estimated ICERs
were to the right of the y-axis, indicating that BSC was
likely to produce higher QALYs than UC. In the mean-
time, these estimates spread across the x-axis, indicating
a higher level of uncertainty in the difference in total
costs between the two groups. The CEAC shows that
the probability of BSC being cost-effective, compared with
UC, was 76% at £20000/QALY and 80% at
£30000/QALY.
Sensitivity analyses
The CCA was performed on 168 participants (80 in the
UC group and 88 in the BSC group). The results sug-
gested that BSC was costlier than UC and more effective,
but ICER indicates that BSC is not cost-effective com-
pared with UC under current maximum acceptable
ICERs at point estimate, with a very high level of uncer-
tainty (Table 2, right; Fig. 1, lower). Figure 2 shows that
the difference in mean values of both costs and utility
between imputed data and complete cases was bigger
in the UC group.
Under theMNARassumption (1), the incremental costs
became –£267, £265 and –£263 when imputed costs
were increased by 10, 20 and 30%, respectively. Under
theMNARassumption (2), the incremental QALYs became
0.014, 0.015 and 0.016 when imputed QALYs were de-
creased by 10, 20 and 30%, respectively. The BSC group
retained dominance over the UC group.
Table 2 Incremental cost-effectiveness analysis results of the primary analysis and complete case analysis.
Primary analysis Complete case analysis
UC (n = 261) BSC (n = 265) UC (n = 80) BSC (n = 88)
Costs Mean (SE) Mean (SD)
BSC – £418 (£10) – £430 (£151)
Usual care services for
smoking cessation
£65 (£6) £52 (£6) £63 (£88) £53 (£98)
Pharmacotherapy prescription £29 (£6) £91 (£13) £29 (£70) £111 (£229)
Primary and community care £4711 (£331) £5101 (£383) £5314 (£5101) £5400 (£6068)
Secondary care £2917 (£670) £1986 (£397) £2419 (£8791) £1754 (£5238)
Antipsychotics prescription £768 (£81) £799 (£84) £704 (£1268) £587 (£654)
Total £8489 (£775) £8447 (£596) £8530 (£11 405) £8434 (£8642)
Incremental costs Mean (95% CI) Mean (95% CI)
Adjusted difference in
mean total costs
a
–£270 (£1690 to £1424) £911 (£2768 to £2631)
Quality of life Mean (SE) Mean (SD)
QALYs 0.647 (0.017) 0.664 (0.015) 0.615 (0.283) 0.679 (0.219)
Incremental QALYs Mean (95% CI) Mean (95% CI)
Adjusted difference in
mean QALYs
b
0.013 (0.008 to 0.045) 0.008 (0.030 to 0.074)
Incremental
cost-effectiveness ratio
Mean (uncertainty) Mean (uncertainty)
ICER BSC dominates (see Fig. 1 upper) £113875 (see Fig. 1 lower)
a
Adjusted for health resource use in the 6 months before randomization, age, gender, pre-existing medical conditions, duration since first diagnosis of severe
mental illness (SMI), with study centre as random effect.
b
Adjusted for the five-level EuroQol 5-dimension (EQ-5D-5 L) utility value at baseline, age, gender,
pre-existing medical conditions, duration since first diagnosis of SMI, with study centre as random effect. ICER = incremental cost-effectiveness ratio;
QALY = quality-adjusted life year; CI = confidence interval; SE = standard error; SD = standard deviation; BSC = bespoke smoking cessation; UC = usual care.
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Secondary analysis
There were 344 participants who had CO-validated
smoking status at both follow-ups and cost of antipsy-
chotics during the trial period. No evidence of a change in
antipsychotics costs between the two 6-month periods of
the trial was found for the quitters. The non-quitters
(n = 286) showed an increase in the cost of antipsychotics
(Z=3.119,P=0.0018, Supporting information, Table S4).
Figure 1 Cost-effectiveness plane (CEP) and cost-effectiveness acceptability curve (CEAC) of the primary analysis (upper) and the complete case
analysis (CCA) (lower) [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2 Comparison of mean health services costs and mean utility scores between primary data set and complete cases [Colour figure can be
viewed at wileyonlinelibrary.com]
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DISCUSSION
The primary analysis found that the BSC intervention for
people with SMI is likely to be cost-effective, comparedwith
usual care, from an NHS and PSS perspective. Although
the BSC intervention was more expensive than usual care
and led to increased prescription of pharmacotherapies,
this did not lead to an increase in overall NHS/PSS costs
in the short term. The sensitivity analyses indicated that
the impact of missing data was more prominent in the
UC group than in the BSC group. The difference in mean
cost of antipsychotics between the two halves of the trial
period was not significant among those who had quit at ei-
ther or both follow-up time-points. Thismight be due to the
short time horizon and the limited number of quitters.
However, there is a small but significant increase among
those who continued to smoke. Although appearing unre-
lated to the BSC intervention, it pointed out that smoking
cessation as a possible way to at least maintain the level
of medication intake for smokers with SMI therefore
strengthened the importance and potential benefits of quit-
ting smoking in this population.
The strength of our trial stemmed from extensive data
collection over health-care resources and the large sample
size. To our knowledge, this is the first large-scale RCT
with a concurrent economic evaluation of a bespoke in-
tervention designed to help people with SMI to quit
smoking. Previous trials have been limited by the sample
size and short follow-up period, and focused more on
pharmacotherapies than the behavioural support [7].
However, a 12-month follow-up period might still be in-
sufficient for a smoking cessation intervention. In addi-
tion, with the large amount of data requested, the
questionnaire became more complex and the burden of
answering increased. This might contribute to the odd
missing data at baseline. Given the low level of missing
data the effect of using mean imputation should be mini-
mal, but there was a potential modest underestimation of
uncertainty as a result. We relied on the primary care
practices to extract data from participants’ medical re-
cords. While this improved the accuracy of prescription in-
formation, the withdrawal and closure of practices caused
a considerable level of missing data, even with mental
health trusts as an alternative data source.
As the complete case analysis is known to produce bi-
ased results, we used the multiple imputation method to
deal with missing data.When undertaking bootstrap to as-
sess the uncertainty of ICER for the imputed data set the
method we used was suggested by Faria et al., which per-
forms bootstrap for each of the imputed data set [27]. Other
methods such as drawing bootstrap samples from the in-
complete data set and performing multiple imputation on
each of the bootstrap samples have also been suggested
[33]. The decision of which method to use might have
affected the uncertainty assessment. However, this is be-
yond the scope of this study.
Although the use of crosswalk mapping function for
EQ-5D-5 L was the requested method for the
reference-case analysis stipulated by NICE [24], the uncer-
tainty associated with mapping function itself is hard to ac-
count for in application. This conversion might also
mitigate the possible benefits of the 5 L system [25]. Fur-
thermore, the validity and responsiveness of EQ-5D-5 L in
measuring people with severe mental illness such as bipo-
lar disorder and schizophrenia have been called into ques-
tion [34,35].
The primary analysis concludes that BSC is likely to be
cost-effective due mainly to the lower costs of health re-
sources use in this group, the main drive of which was
lowered secondary care costs. This is consistent with what
one study in the United States found, which indicated that
tobacco cessation treatment for smokers hospitalized with
psychiatric disorders may decrease rehospitalization risk
due to the possible broader therapeutic benefit [36]. In-
stances were also observed where the MH-SCPs were able
to identify early signs of decline inmental health and liaised
with the mental health-care team for additional care. This
is likely to have prevented further deterioration and the
need for more intensive care.
Since undertaking the SCIMITAR+ trial, the way of
commissioning smoking cessation services in England have
changed and some services have been contracted-out to
third parties. This might undermine the perspective taken
in this study, as the reduced costs to the NHS would not
be seen as a direct benefit.
More research is recommended to explore the integra-
tion of smoking cessation interventions with routine men-
tal health services so as to maximize the benefits of
intensive sessions. The long-term impact of smoking cessa-
tion among people with SMIs should also be studied, espe-
cially in relation to the use of antipsychotics, and the
mechanism behind the lowered hospitalization for those
who receive smoking cessation intervention.
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